1. An early-stage Amgen, specializing in gene therapies for cancer and diabetes.

2. Like a clinical-stage Vertex Pharmaceuticals, developing gene therapies for lung cancer and diabetes.

• REQORSA (GPX-001): A lead product candidate, this gene therapy is in development for the treatment of non-small cell lung cancer and small cell lung cancer.
• GPX-002: A preclinical stage gene therapy being developed for diabetes.

Genprex, Inc. (GNPX) is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes. As a clinical-stage company, its products (REQORSA and GPX-002) are currently in various stages of clinical trials and preclinical development, respectively. They have not yet received regulatory approval for commercial sale.

Therefore, Genprex does not currently have major customers that purchase its therapeutic products. The company's primary activities involve research and development, conducting clinical trials, and pursuing regulatory approvals rather than commercial sales.

Ryan M. Confer, MS President, Chief Executive Officer, and Chief Financial Officer

Ryan M. Confer was appointed President and Chief Executive Officer of Genprex in May 2024, and has served as the company's Chief Financial Officer since September 2016. He joined Genprex in 2011, serving in various capacities including business manager, and Chief Operating and Financial Officer. Mr. Confer has over ten years of entrepreneurial experience in planning, launching, developing, and growing emerging technology companies, and has held C-level and Vice President roles in several early-stage technology companies since 2008. Notably, he was the VP of Customer Experience and then VP of Strategy for KaiNexus, Inc., a software company focused on continuous improvement. Prior to his entrepreneurial endeavors, Mr. Confer was a business development consultant for the University of Texas at Austin's IC2 Institute, where he assessed the commercialization potential of nascent technologies. From 2006 to 2009, he also managed a $500 million early-stage technology investment fund. Mr. Confer has consulted for Genprex since its inception in 2009 through his own firm, Confer Capital, Inc.

Mark Berger, M.D. Chief Medical Officer

Dr. Mark Berger was appointed Chief Medical Officer of Genprex in September 2021. Before joining Genprex, he served as Senior Vice President-Clinical Research at Kadmon Corporation from 2013 to 2017, where he was responsible for all aspects of new drug development, including oncology programs in non-small cell lung cancer and breast cancer. Prior to Kadmon, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013, and before that, Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led clinical strategy and trial management for two oncology agents.

Thomas Gallagher, Esq. Senior Vice President of Intellectual Property & Licensing

Thomas Gallagher serves as the Senior Vice President of Intellectual Property & Licensing at Genprex.

Suzanne Thornton-Jones, Ph.D. Senior Vice President, Regulatory Affairs and Quality

Suzanne Thornton-Jones is the Senior Vice President, Regulatory Affairs and Quality at Genprex.

David M. Schloss Senior Vice President of Human Resources

David M. Schloss holds the position of Senior Vice President of Human Resources at Genprex.

Here are the key risks to Genprex's business:

1. Clinical Trial Failure and Regulatory Approval: As a clinical-stage gene therapy company, Genprex's success hinges on its ability to successfully complete clinical trials for its lead product candidates, REQORSA (GPX-001) for lung cancer and GPX-002 for diabetes, and subsequently obtain regulatory approvals. The development of novel gene therapies is subject to extensive and evolving regulatory requirements, and changes in these policies or increased scrutiny could delay or prevent product approval. Failures in clinical trials, delays in enrollment, or inability to meet primary or secondary endpoints would severely impact the company's valuation and future prospects.
2. Financing and Liquidity: Genprex faces significant operational risks due to its need for substantial additional funding to continue the development and potential commercialization of its product candidates. The company has a history of recurring losses and an accumulated deficit, and it does not expect to be profitable in the foreseeable future. This raises substantial doubt about its ability to continue as a going concern, indicating a reliance on future equity offerings, collaborations, or other financing arrangements, which could lead to significant shareholder dilution or even cessation of operations if not secured.
3. Competition and Market Acceptance: Genprex operates in highly competitive markets for gene therapy, oncology, and diabetes treatments. It faces competition from various biotechnology and pharmaceutical companies, many of which possess greater financial resources and more extensive research and development capabilities. These competitors may develop more effective or widely accepted products, potentially diminishing the market opportunity for Genprex's drug candidates.

Genprex, Inc. (NASDAQ: GNPX) operates in the addressable markets of non-small cell lung cancer, small cell lung cancer, and diabetes.

REQORSA (GPX-001) for Lung Cancer

• Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer therapeutics market was valued at approximately USD 38.49 billion in 2025 and is projected to grow to approximately USD 74.99 billion by the end of 2034. In North America, the market was valued at USD 17.15 billion in 2025 and is anticipated to maintain a dominant share.
• Small Cell Lung Cancer (SCLC): The global small cell lung cancer therapeutics market size is projected to be approximately USD 6.52 billion in 2025, with an expected increase to USD 17.59 billion by 2033. North America accounted for over 40% of the global revenue in 2025, with a market size of approximately USD 2.61 billion.

GPX-002 for Diabetes

• Diabetes Gene Therapy / Next-Generation Diabetes Therapy: The global Next Generation Diabetes Therapy and Drug Delivery market size was approximately USD 10.22 billion in 2024 and is expected to grow to approximately USD 27.51 billion by 2031. North America held a major market share of over 40% of the global revenue in 2024, with a market size of approximately USD 4.09 billion.
• Overall Diabetes Treatment Market: More broadly, the global diabetes drugs market was valued at approximately USD 99.88 billion in 2024 and is projected to reach approximately USD 218.8 billion by 2032. North America accounted for 21% of the market share in 2023.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is currently a pre-revenue company, meaning its future revenue growth is entirely dependent on the successful clinical development and eventual commercialization of its lead product candidates. Over the next 2-3 years, the primary drivers of future revenue growth will stem from critical advancements in its oncology and diabetes gene therapy programs.

Here are 3-5 expected drivers of future revenue growth for Genprex:

1. Advancement of REQORSA (GPX-001) in Non-Small Cell Lung Cancer (NSCLC) through Clinical Trials: The progression of the Acclaim-1 clinical trial for REQORSA in combination with Tagrisso to treat NSCLC is a key driver. The successful completion of the Phase 1 portion and the ongoing Phase 2a expansion, with an interim analysis expected by the end of 2026 and the potential start of Phase 2b in 2027, will be crucial milestones toward regulatory submission and potential market entry. Positive outcomes from these trials could demonstrate efficacy and safety, paving the way for future regulatory approvals and commercialization in a significant market.
2. Advancement of REQORSA (GPX-001) in Small Cell Lung Cancer (SCLC) through Clinical Trials: The continued progress of the Acclaim-3 Phase 1/2 clinical trial, evaluating REQORSA in combination with Tecentriq for SCLC, is another vital driver. REQORSA has already received Fast Track Designation and Orphan Drug Designation from the U.S. FDA for SCLC, which could expedite its development and review process. Successful trial results would move the company closer to regulatory approval and market access for this difficult-to-treat cancer.
3. Initiation and Progression of Human Clinical Trials for GPX-002 in Diabetes: Genprex's diabetes gene therapy candidate, GPX-002, which targets both Type 1 and Type 2 diabetes, has shown positive preclinical data. A significant driver will be the successful engagement with the FDA for Investigational New Drug (IND)-enabling studies, with a meeting scheduled for the first quarter of 2026. The subsequent initiation and progression of human clinical trials for GPX-002 would be a critical de-risking event and a substantial step towards realizing future revenue potential, even if commercialization is beyond the immediate 2-3 year horizon.
4. Strategic Partnerships and Collaborations: While not a direct product, the company's ability to establish and leverage strategic partnerships for the development, manufacturing, and potential commercialization of its therapies is a significant driver. Genprex has already undertaken manufacturing scale-up for REQORSA and engaged Contract Development and Manufacturing Organizations (CDMOs) for GPX-002. Such collaborations can provide necessary resources, expertise, and market access, thereby accelerating the path to market for its innovative gene therapies.

Share Issuance

• Genprex had 2.32 million shares outstanding (as of March 2026).
• The number of shares outstanding increased by 922.94% in one year.
• The company executed a 1-for-50 reverse stock split on October 21, 2025.

Capital Expenditures

• Genprex's capital expenditures were listed as "n/a" in one financial overview.
• The company's free cash flow of -$15.08 million provided weak coverage of capital expenditures, which were indicated as "1" (likely a negligible amount).
• Genprex generated -$1.7 million in free cash flow in Q3 2024, representing cash available after capital expenditures.